{
    "clinical_study": {
        "@rank": "114110", 
        "acronym": "esozao", 
        "arm_group": {
            "arm_group_label": "Zoledronic Acid and Aromatase Inhibitors", 
            "arm_group_type": "Experimental", 
            "description": "Zoledronic Acid and Aromatase Inhibitors for Adjuvant Therapy"
        }, 
        "brief_summary": {
            "textblock": "Select patients of primary breast cancer whose hormone receptor is positive and accepted\n      postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with\n      zoledronic acid 4mg intravenous infusion every six months until the end of the aromatase\n      treatment. Assess the disease-free survival; overall survival; combination of security, as\n      well as the situation of bone loss."
        }, 
        "brief_title": "Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The investigators select patients of primary breast cancer whose hormone receptor is\n      positive and accepted postoperative adjuvant aromatase inhibitors for endocrine\n      treatment.Treat them with zoledronic acid 4mg intravenous infusion every six months until\n      the end of the aromatase treatment. Assess the disease-free survival; overall survival;\n      combination of security, as well as the situation of bone loss."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Karnofsky\u226570\n\n          2. Provision of informed consent\n\n          3. Pathological confirmation of breast cancer\n\n          4. Hormone receptor-positive and accept aromatase inhibitors for adjuvant endocrine\n             therapy\n\n          5. Not previously received treatment with bisphosphonate\n\n          6. Laboratory criteria:\n\n             PLT\u2265100*109/L WBC\u22654000/mm3 HGB\u226510g/dl GOT,GPT,ALP\u22642*ULN TBIL,DBIL,CCr\u22641.5*ULN\n\n          7. Surgery , radiotherapy and chemotherapy has finished\n\n        Exclusion Criteria:\n\n          1. Pregnant of lactation woman\n\n          2. History of organ transplantation\n\n          3. With mental disease\n\n          4. With severe infection or active gastrointestinal ulcers\n\n          5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or\n             diabetes\n\n          6. Disease-free period of other malignant tumor is less than 5 years(except cured basal\n             cell skin cancer and cervical carcinoma in situ)\n\n          7. With heart disease\n\n          8. Experimental drug allergy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654367", 
            "org_study_id": "jzhang2"
        }, 
        "intervention": {
            "arm_group_label": "Zoledronic Acid and Aromatase Inhibitors", 
            "description": "Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy", 
            "intervention_name": "Zoledronic Acid and Aromatase Inhibitors", 
            "intervention_type": "Drug", 
            "other_name": "Zoledronic Acid and Aromatase Inhibitors"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Zoledronic acid", 
                "Diphosphonates", 
                "Aromatase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 26, 2012", 
        "location": {
            "contact": {
                "last_name": "ZHANG SHENG, DOCTOR", 
                "phone": "86-022-23340123", 
                "phone_ext": "2901"
            }, 
            "contact_backup": {
                "last_name": "ZHANG SHENG, DORTOR", 
                "phone": "86-022-23340123", 
                "phone_ext": "2901"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300060"
                }, 
                "name": "Tianjin Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "ZHANG JIN, PROFESSOR", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Effectiveness and Safety of Treating Operable Breast Cancer by the Adjuvant Therapy of Zoledronic Acid and Aromatase Inhibitors and/or Ovarian Function Inhibition", 
        "other_outcome": {
            "description": "Recurrence or death", 
            "measure": "Recurrence or death", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "overall_official": {
            "affiliation": "TIANJIN CANCER HOSPITAL", 
            "last_name": "Jin Zhang, Professor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "therapeutic assessment", 
            "measure": "therapeutic assessment", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654367"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tianjin Medical University", 
            "investigator_full_name": "Zhang jin", 
            "investigator_title": "Tianjin Medical University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Adverse reactions and disease-free survival", 
            "measure": "Adverse reactions and disease-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "Tianjin Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tianjin Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}